Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Povetacicept by Alpine Immune Sciences for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
Povetacicept by Alpine Immune Sciences for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia. According...
Povetacicept by Alpine Immune Sciences for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase II for IgA Nephropathy (Berger's Disease). According...
Povetacicept by Alpine Immune Sciences for Membranous Glomerulonephritis: Likelihood of Approval
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase II for Membranous Glomerulonephritis. According to GlobalData,...
Povetacicept by Alpine Immune Sciences for Lupus Nephritis: Likelihood of Approval
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase II for Lupus Nephritis. According to GlobalData,...
Povetacicept by Alpine Immune Sciences for Systemic Lupus Erythematosus: Likelihood of Approval
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to...
Risk adjusted net present value: What is the current valuation of Alpine Immune Sciences's Povetacicept?
Povetacicept is a fusion protein commercialized by Alpine Immune Sciences, with a leading Phase II program in Idiopathic Thrombocytopenic Purpura...